Best CDMOs in Europe — Ranked by Signal Score · 2026
· updated as new inspection, certificate, and trial data enters the platform
64
CDMOs in region
64
Fully scored
23
With FDA records
83
FDA inspections
358
EMA/MHRA GMP certs
CDMO Signal tracks 64 biopharma CDMOs with confirmed Europe manufacturing facilities, of which 64 are fully scored across the four-pillar composite Signal Score. Across all modalities, Charles River Laboratories, ReciBioPharm, and Novartis lead the Europe ranking by composite score. Signal Score integrates FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. For modality-specific rankings within Europe — AAV, cell therapy, biologics, and 10 other tracked modalities — see the modality-region breakdown below. Full methodology at cdmosignal.com/methodology.
European CDMOs ranked by CDMO Signal's composite Signal Score, filtered to manufacturers with confirmed EU, UK, or Swiss facilities. This ranking is the subset of our global directory with European manufacturing presence — a CDMO with EU + US + Asia sites appears in each corresponding region ranking. Filtering is derived from each CDMO's declared facility locations.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
90.9 | 98.3 | 8 insp · 11 GMP | Limited | 0 programs |
| 2 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 3 |
Novartis
Basel, Switzerland
|
87.1 | 93.1 | 16 insp · 67 GMP | — | 135 programs |
| 4 |
BNT
BioNTech (Mfg Services)
Mainz, DE · Marburg, DE
|
84.9 | 100.0 | 0 insp · 8 GMP | — | 28 programs |
| 5 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
84.8 | 100.0 | 0 insp · 23 GMP | 0 programs | |
| 6 |
MN
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.3 | 99.6 | 1 insp · 6 GMP | Limited | 0 programs |
| 7 |
RB
Richter BioLogics
Hamburg, Germany
|
82.9 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 8 |
TK
Takeda
Boston, MA · Zurich, CH
|
81.9 | 99.6 | 4 insp · 18 GMP | — | 100 programs |
| 9 |
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
|
81.8 | 98.7 | 2 insp · 2 GMP | — | 22 programs |
| 10 |
WK
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
|
81.6 | 100.0 | 0 insp · 13 GMP | — | 0 programs |
| 11 |
SC
SCTbio
Prague, Czech Republic
|
81.6 | 100.0 | 0 insp · 5 GMP | — | 0 programs |
| 12 |
EF
Eurofins CDMO
Planegg, DE · San Diego, CA
|
81.6 | 100.0 | 5 insp · 0 GMP | — | 0 programs |
| 13 |
CD
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
|
81.1 | 98.9 | 4 insp · 10 GMP | — | 0 programs |
| 14 |
RC
RoslinCT
Edinburgh, UK · Hopkinton, MA
|
80.3 | 99.0 | 1 insp · 1 GMP | Available | 0 programs |
| 15 |
CF
CELLforCURE (SEQENS)
Les Ulis, FR
|
80.3 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 16 |
KE
Kaneka Eurogentec
Seraing, BE
|
80.3 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 17 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
80.2 | 97.1 | 4 insp · 8 GMP | — | 0 programs |
| 18 |
BA
Bachem
Bubendorf, CH
|
80.0 | 95.4 | 3 insp · 0 GMP | — | 0 programs |
| 19 |
NV
Novartis Contract Manufacturing
Morris Plains, NJ · Stein, CH
|
79.9 | 93.1 | 1 insp · 0 GMP | Constrained | 284 programs |
| 20 |
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | Available | 0 programs |
| 21 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
78.6 | 100.0 | 2 insp · 23 GMP | Available | 2 programs |
| 22 |
AA
Ascend Advanced Therapies
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 23 |
NG
NecstGen
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 24 |
ET
Exothera
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 25 |
PG
ProBioGen
Berlin, DE
|
78.1 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 26 |
OR
Ori Biotech
London, UK
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 27 |
CE
Celonic
Basel, Switzerland
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 28 |
XP
eXmoor Pharma
Bristol, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 29 |
AD
Advent Bioservices
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 30 |
BV
Biovian
Turku, Finland
|
78.0 | 99.8 | 1 insp · 4 GMP | — | 0 programs |
| 31 |
RB
Rentschler Biopharma
Laupheim, Germany
|
77.9 | 99.6 | 1 insp · 2 GMP | — | 0 programs |
| 32 |
VG
Viralgen Vector Core
San Sebastián, Spain
|
76.8 | 100.0 | 0 insp · 4 GMP | Available | 0 programs |
| 33 |
SY
Symbiosis Pharmaceutical Services
Stirling, United Kingdom
|
76.8 | 100.0 | 1 insp · 9 GMP | — | 0 programs |
| 34 |
CY
Cell-Easy
Toulouse, FR
|
76.8 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 35 |
CN
Cellin Technologies
Luxembourg, LU
|
76.8 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 36 |
HH
HiTech Health
London, United Kingdom
|
76.8 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 37 |
BM
Biomay AG
Vienna, Austria
|
76.3 | 98.9 | 2 insp · 11 GMP | — | 0 programs |
| 38 |
OX
Oxford Biomedica
Oxford, United Kingdom
|
76.2 | 100.0 | 0 insp · 13 GMP | Available | 7 programs |
| 39 |
Lonza
Basel, Switzerland
|
76.0 | 95.7 | 2 insp · 8 GMP | — | 1 programs |
| 40 |
CVC
CureVac (CDMO Services)
Tubingen, DE
|
75.3 | 100.0 | 0 insp · 7 GMP | — | 4 programs |
| 41 |
CG
Cytiva (Mfg Services)
Marlborough, MA · Uppsala, SE
|
74.0 | — | — | — | 0 programs |
| 42 |
Catalent
Bagsværd, Denmark (operating under Novo Holdings; key US DP site: Bloomington, IN)
|
73.1 | 74.9 | 12 insp · 37 GMP | — | 0 programs |
| 43 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
73.1 | 74.9 | 1 insp · 0 GMP | Available | 0 programs |
| 44 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
73.0 | 95.7 | 1 insp · 0 GMP | Limited | 0 programs |
| 45 |
MB
Miltenyi Biotec
Bergisch Gladbach, Germany
|
73.0 | 100.0 | 0 insp · 2 GMP | — | 8 programs |
| 46 |
AX
Axolabs (Nuvisan)
Kulmbach, Germany
|
72.6 | 99.0 | 1 insp · 0 GMP | — | 3 programs |
| 47 |
RT
ReiThera
Rome, IT
|
71.1 | 100.0 | 0 insp · 4 GMP | — | 1 programs |
| 48 |
BP
BSP Pharmaceuticals
Latina, Italy
|
70.5 | 83.6 | 7 insp · 14 GMP | — | 0 programs |
| 49 |
PP
PolyPeptide Group
Torrance, CA · Strasbourg, FR · Malmo, SE
|
66.1 | 74.2 | 3 insp · 0 GMP | — | 0 programs |
| 50 |
SI
Simtra BioPharma Solutions
Bloomington, IN · Halle, DE
|
65.7 | 73.3 | 0 insp · 1 GMP | — | 0 programs |
| 51 |
RA
Recipharm Advanced Bio
Stockholm, Sweden
|
63.0 | — | — | — | 0 programs |
| 52 |
HP
HIPRA Biotech Services
Amer, Spain
|
63.0 | — | — | — | 0 programs |
| 53 |
AB
Asklepios BioPharmaceutical (AskBio)
Research Triangle, NC · San Sebastian, ES
|
61.8 | — | — | — | 10 programs |
| 54 |
CP
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
|
59.0 | — | — | — | 0 programs |
| 55 |
EX
Excellos
La Rochelle, France
|
59.0 | — | — | — | 0 programs |
| 56 |
CZ
Cellex Cell Professionals
Cologne, Germany
|
59.0 | — | — | — | 0 programs |
| 57 |
AM
Anemocyte
Gerenzano, IT
|
59.0 | — | — | — | 0 programs |
| 58 |
CV
CEVEC Pharmaceuticals
Cologne, DE
|
56.5 | — | — | — | 0 programs |
| 59 |
CX
CellGenix
Freiburg, DE
|
56.5 | — | — | — | 0 programs |
| 60 |
QB
Quantoom Biosciences
Gosselies, BE
|
56.5 | — | — | — | 0 programs |
| 61 |
EH
Ethris
Planegg, DE
|
56.5 | — | — | — | 0 programs |
| 62 |
PF
PlasmidFactory
Bielefeld, Germany
|
56.5 | — | — | — | 0 programs |
| 63 |
EXO
ExoXpert (EXO Biologics)
Liege, BE
|
56.5 | — | — | — | 0 programs |
| 64 |
EV
Evox Therapeutics
Oxford, UK
|
56.5 | — | — | — | 0 programs |
EMA and MHRA regulatory considerations for European-manufactured programs
European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.
QP release requirements and how they affect CDMO selection
Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.
Which European CDMOs also cover FDA (US) regulatory geography?
European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.
Browse by modality within Europe
Modality-specific rankings for Europe-manufactured programs. Each page filters the modality's global ranking to CDMOs with confirmed Europe facilities.
AAV / Gene Therapy (28)
CAR-T (13)
Lentiviral Vector (16)
Cell Therapy (27)
mRNA / LNP (17)
Plasmid DNA (11)
Biologics / mAb (10)
Oligonucleotide / ASO (5)
Adenoviral Vector (4)
Gene Editing (2)
Exosome / Extracellular Vesicle (2)
Recombinant Proteins (8)
ADC (Antibody-Drug Conjugate) (6)
Gene Therapy (29)
Cell & Gene Therapy (44)
Viral Vector (28)